Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13037128 | 0.91 | TAAR1 (0.58) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL2601968 | 0.88 | HRH2 (0.52) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL8828180 | 0.87 | TAAR1 (0.62) | TAAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16312618 | 0.84 | HRH2 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3HRH2 | |
| SCHEMBL3556419 | 0.82 | CYP3A4 (0.50) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL13037131 | 0.82 | HRH2 (0.48) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| Hydrochloric Acid SCHEMBL3562575 | 0.81 | MEN1 (0.47) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL19500871 | 0.79 | LTA4H (0.52) | TAAR1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL3149388 | 0.79 | TAAR1 (0.54) | TAAR1SLC6A4SLC6A2SLC6A3HRH2 | |
| SCHEMBL8828505 | 0.78 | TAAR1 (0.50) | TAAR1MEN1KMT2AKCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6864263-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6849739-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6846829-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6841674-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-6841673-B2 | N-heterocyclic derivatives as nos inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-6747031-B2 | MUSCLE RELAXANTS, CONTROLLING IMMUNOLOGY, STROKES, ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6670473-B2 | Inhibitors of nitric oxide synthase (nos) | BERLEX LABORATORIES, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1206467-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TAAR1 1040/4885SLC6A4 1509/4885SLC6A2 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.